NHS expands abiraterone access for high-risk prostate
NHS England has widened abiraterone acetate access for adults with high-risk non-metastatic prostate cancer, with treatment expected to reach eligible patients within weeks. The change matters because trials show higher 6-year survival and fewer progressions to incurable spread when abiraterone is used earlier alongside standard care. It also removes a long-running access gap that left […]